1-4 of 4
Lara Stepan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Lara Stepan, Sahar Ansari, Abood Okal, Justine Dell'Aringa, Ethan G. Thompson, Alessandro Crotta, Victor A. Chow, Jeremy S. Abramson, Manali Kamdar, Scott R. Solomon, Patrick B. Johnston, Bertram Glass, Pim Mutsaers, Jon E. Arnason, Stephan Mielke, Mazyar Shadman, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Veronika Bachanova, Sami Ibrahimi, Jacob Chabon, David Kurtz, Ash A. Alizadeh, Leanne Peiser
Journal: Blood
Blood (2024) 144 (Supplement 1): 72.
https://doi.org/10.1182/blood-2024-199813
Published: 2024
Journal Articles

Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study

Dasom Lee, Brian J. Sworder, Lara Stepan, Abood Okal, Chang-Pin Huang, Xiaoman Kang, James Hamilton, Charles Macaulay, Mari Olsen, Chih Long Liu, Maximilian Diehn, Leanne Peiser, David Kurtz, Ash A. Alizadeh
Journal: Blood
Blood (2024) 144 (Supplement 1): 3410.
https://doi.org/10.1182/blood-2024-200924
Published: 2024
Journal Articles

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Lara Stepan, Sahar Ansari, Abood Okal, Justine Dell'Aringa, Ethan Thompson, Alessandro Crotta, Victor A Chow, Jeremy S. Abramson, Manali Kamdar, Jacob J. Chabon, Gregory Hogan, David M. Kurtz, Ash A. Alizadeh, Leanne Peiser
Journal: Blood
Blood (2023) 142 (Supplement 1): 225.
https://doi.org/10.1182/blood-2023-181007
Published: 2023
Journal Articles

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Manali Kamdar, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim G.N.J. Mutsaers, Francisco J. Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, David G. Maloney, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Lara Stepan, Ken Ogasawara, Timothy Mack, Jeremy S. Abramson
Journal: Blood
Blood (2021) 138 (Supplement 1): 91.
https://doi.org/10.1182/blood-2021-147913
Published: 2021